13.49
price up icon6.81%   0.86
pre-market  Vorhandelsmarkt:  13.91   0.42   +3.11%
loading
Schlusskurs vom Vortag:
$12.63
Offen:
$13.01
24-Stunden-Volumen:
5.61M
Relative Volume:
1.23
Marktkapitalisierung:
$1.40B
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-2.4617
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
+17.51%
1M Leistung:
+46.63%
6M Leistung:
+22.52%
1J Leistung:
-46.74%
1-Tages-Spanne:
Value
$12.80
$13.51
1-Wochen-Bereich:
Value
$11.60
$13.57
52-Wochen-Spanne:
Value
$5.90
$27.42

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
Firmenname
Intellia Therapeutics Inc
Name
Telefon
857-285-6200
Name
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Name
Mitarbeiter
598
Name
Twitter
@intelliatweets
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
NTLA's Discussions on Twitter

Vergleichen Sie NTLA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NTLA
Intellia Therapeutics Inc
13.49 1.19B 45.97M -508.80M -382.65M -5.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-21 Hochstufung Wolfe Research Peer Perform → Outperform
2025-03-05 Eingeleitet H.C. Wainwright Buy
2025-02-28 Herabstufung Goldman Neutral → Sell
2025-02-28 Herabstufung JP Morgan Overweight → Neutral
2025-01-27 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-02-23 Herabstufung Goldman Buy → Neutral
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-04-13 Eingeleitet Canaccord Genuity Buy
2023-03-21 Eingeleitet Bernstein Outperform
2023-03-14 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-02-01 Eingeleitet Cantor Fitzgerald Overweight
2023-01-24 Hochstufung Citigroup Sell → Neutral
2023-01-19 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 Eingeleitet Morgan Stanley Overweight
2022-09-21 Eingeleitet JP Morgan Overweight
2022-09-01 Eingeleitet Citigroup Sell
2022-06-17 Eingeleitet BMO Capital Markets Market Perform
2022-06-16 Eingeleitet BofA Securities Buy
2022-04-28 Eingeleitet Credit Suisse Outperform
2022-02-18 Eingeleitet William Blair Outperform
2022-02-07 Hochstufung Oppenheimer Perform → Outperform
2022-01-31 Eingeleitet Cowen Outperform
2022-01-07 Eingeleitet Piper Sandler Overweight
2021-10-05 Eingeleitet Guggenheim Buy
2021-09-24 Eingeleitet Stifel Buy
2021-06-28 Bestätigt H.C. Wainwright Buy
2021-06-11 Eingeleitet H.C. Wainwright Buy
2021-05-07 Hochstufung ROTH Capital Neutral → Buy
2021-05-04 Eingeleitet RBC Capital Mkts Outperform
2021-03-04 Eingeleitet JMP Securities Mkt Outperform
2020-12-22 Herabstufung Robert W. Baird Outperform → Neutral
2020-10-27 Eingeleitet Truist Buy
2020-10-14 Eingeleitet Wells Fargo Overweight
2020-09-18 Eingeleitet Goldman Buy
2020-02-28 Hochstufung Oppenheimer Perform → Outperform
2020-02-14 Herabstufung Wedbush Outperform → Neutral
2019-11-01 Hochstufung Raymond James Mkt Perform → Outperform
2019-07-09 Eingeleitet Robert W. Baird Outperform
2019-06-10 Eingeleitet ROTH Capital Neutral
2019-05-03 Hochstufung Wedbush Neutral → Outperform
2019-04-12 Eingeleitet Evercore ISI Outperform
2018-11-02 Herabstufung Wedbush Outperform → Neutral
2018-10-29 Eingeleitet Credit Suisse Neutral
2018-09-21 Eingeleitet Raymond James Mkt Perform
2018-05-15 Hochstufung Chardan Capital Markets Neutral → Buy
2018-03-08 Eingeleitet JMP Securities Mkt Outperform
2017-11-01 Bestätigt Jefferies Buy
2017-06-22 Fortgesetzt Jefferies Buy
2017-03-28 Eingeleitet Chardan Capital Markets Buy
2016-08-05 Hochstufung Jefferies Hold → Buy
Alle ansehen

Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Intellia Therapeutics Inc. a good long term investmentOutstanding stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Intellia Therapeutics Inc. Stock Analysis and ForecastConsistently high yield - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Intellia Therapeutics Inc. stock priceDouble or triple returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options - Nasdaq

Jul 21, 2025
pulisher
Jul 19, 2025

What analysts say about Intellia Therapeutics Inc. stockOverwhelming financial success - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Intellia Therapeutics: A High-Volatility, High-Reward Play in the CRISPR Revolution - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At ‘Buy’ (NTLA) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 17, 2025

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks

Jul 17, 2025
pulisher
Jul 16, 2025

Intellia Faces The Biotech Balancing Act As Shares Slide - Finimize

Jul 16, 2025
pulisher
Jul 16, 2025

ATTR Amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks

Jul 15, 2025
pulisher
Jul 09, 2025

Intellia Therapeutics (NTLA) Soars 9.08% on Phase III Trial - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Possible Bearish Signals With Intellia Therapeutics Insiders Disposing Stock - simplywall.st

Jul 09, 2025
pulisher
Jul 08, 2025

Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital - The Globe and Mail

Jul 08, 2025
pulisher
Jul 07, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

Gene Editing Leader Intellia Expands Team with 23,800 Share RSU Grant Package - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

Intellia Gains 29.8% in a Month: How Should You Play the Stock? - Nasdaq

Jul 07, 2025
pulisher
Jul 03, 2025

Insider Sell: Eliana Clark Sells Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus

Jul 03, 2025
pulisher
Jul 03, 2025

Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data - Insider Monkey

Jul 03, 2025
pulisher
Jul 02, 2025

Insider Sell Alert: Jesse Goodman Sells Shares of Intellia Thera - GuruFocus

Jul 02, 2025
pulisher
Jul 02, 2025

The Best Biotech Stocks to Buy - Morningstar

Jul 02, 2025
pulisher
Jun 28, 2025

Intellia Therapeutics gets FDA RMAT status for its heart disorder treatment - MSN

Jun 28, 2025
pulisher
Jun 25, 2025

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Yahoo Finance

Jun 25, 2025
pulisher
Jun 23, 2025

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress - Insider Monkey

Jun 23, 2025
pulisher
Jun 22, 2025

Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress. - Yahoo Finance

Jun 22, 2025
pulisher
Jun 21, 2025

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely? - Yahoo Finance

Jun 21, 2025
pulisher
Jun 18, 2025

Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView

Jun 18, 2025
pulisher
Jun 18, 2025

Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News

Jun 18, 2025
pulisher
Jun 17, 2025

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive

Jun 17, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics (NTLA) Receives Reiterated Buy Rating with Stable Price Target | NTLA Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics Announces Positive Phase 1 Trial Data - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks - MarketScreener

Jun 16, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Ph - GuruFocus

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire

Jun 15, 2025
pulisher
Jun 15, 2025

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Revolutionary Gene Therapy Eliminates HAE Attacks for 2 Years: Breakthrough Phase 1 Trial Results - Stock Titan

Jun 15, 2025
pulisher
Jun 14, 2025

Intellia Therapeutics’ SWOT analysis: gene editing stock faces pivotal year - Investing.com

Jun 14, 2025
pulisher
Jun 12, 2025

Intellia Therapeutics Holds Annual Stockholders’ Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 10, 2025

California State Teachers Retirement System Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World

Jun 10, 2025
pulisher
Jun 06, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - mx.advfn.com

Jun 05, 2025
pulisher
Jun 04, 2025

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise

Jun 04, 2025

Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):